JP2017520575A5 - - Google Patents

Download PDF

Info

Publication number
JP2017520575A5
JP2017520575A5 JP2016575335A JP2016575335A JP2017520575A5 JP 2017520575 A5 JP2017520575 A5 JP 2017520575A5 JP 2016575335 A JP2016575335 A JP 2016575335A JP 2016575335 A JP2016575335 A JP 2016575335A JP 2017520575 A5 JP2017520575 A5 JP 2017520575A5
Authority
JP
Japan
Prior art keywords
cad
seq
sequence
subdomain
heterodimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016575335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017520575A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/054829 external-priority patent/WO2016001810A1/en
Publication of JP2017520575A publication Critical patent/JP2017520575A/ja
Publication of JP2017520575A5 publication Critical patent/JP2017520575A5/ja
Pending legal-status Critical Current

Links

JP2016575335A 2014-07-01 2015-06-26 二重特異的ヘテロ二量体ダイアボディおよびその使用 Pending JP2017520575A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462019762P 2014-07-01 2014-07-01
US62/019,762 2014-07-01
US201562148920P 2015-04-17 2015-04-17
US62/148,920 2015-04-17
PCT/IB2015/054829 WO2016001810A1 (en) 2014-07-01 2015-06-26 Bispecific heterodimeric diabodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2017520575A JP2017520575A (ja) 2017-07-27
JP2017520575A5 true JP2017520575A5 (enExample) 2018-08-02

Family

ID=53718063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016575335A Pending JP2017520575A (ja) 2014-07-01 2015-06-26 二重特異的ヘテロ二量体ダイアボディおよびその使用

Country Status (17)

Country Link
US (2) US9884921B2 (enExample)
EP (1) EP3164417A1 (enExample)
JP (1) JP2017520575A (enExample)
KR (1) KR20170010863A (enExample)
CN (1) CN106661119A (enExample)
AU (2) AU2015283704A1 (enExample)
BR (1) BR112016030740A2 (enExample)
CA (1) CA2895659A1 (enExample)
CO (1) CO2017000016A2 (enExample)
IL (1) IL249889A0 (enExample)
MX (1) MX2016017393A (enExample)
PE (1) PE20170286A1 (enExample)
PH (1) PH12016502491A1 (enExample)
RU (1) RU2016151645A (enExample)
SG (1) SG11201609707WA (enExample)
TW (2) TW201936638A (enExample)
WO (1) WO2016001810A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102612367B1 (ko) 2014-12-05 2023-12-12 메모리얼 슬로안 케터링 캔서 센터 G-단백질 커플화 수용체를 표적화하는 키메라 항원 수용체 및 그의 용도
RU2020120613A (ru) 2014-12-05 2021-12-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Антитела, нацеленные на рецептор, связанный с g-белками, и способы их применения
JP6907124B2 (ja) * 2015-04-17 2021-07-21 アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH Cdh3及びcd3に対する二重特異性抗体構築物
CN108137706A (zh) * 2015-07-15 2018-06-08 酵活有限公司 药物缀合的双特异性抗原结合构建体
JP6954842B2 (ja) 2015-12-25 2021-10-27 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
PE20181889A1 (es) 2016-04-28 2018-12-11 Chugai Pharmaceutical Co Ltd Preparaciones que contienen anticuerpos
US20190185578A1 (en) * 2016-07-29 2019-06-20 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
CN106496331B (zh) * 2016-11-08 2020-03-13 北京智岭生物医药科技有限公司 一种FSH-Fc融合蛋白及其制备方法和用途
KR20240023449A (ko) 2017-02-08 2024-02-21 드래곤플라이 쎄라퓨틱스, 인크. 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
WO2018177371A1 (en) * 2017-03-29 2018-10-04 Taipei Medical University Antigen-specific t cells and uses thereof
EP3601346A1 (en) * 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018178055A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
CN108866635B (zh) * 2017-05-09 2021-11-26 安升(上海)医药科技有限公司 多特异性蛋白药物及其文库、以及制备方法和应用
MX2019014480A (es) * 2017-06-02 2020-01-23 Pfizer Proteinas recombinantes robo2, composiciones, metodos y usos de las mismas.
WO2018237341A1 (en) * 2017-06-22 2018-12-27 Development Center For Biotechnology A TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT FOR CANCER THERAPY
MY204641A (en) 2017-09-29 2024-09-06 Chugai Pharmaceutical Co Ltd Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
KR101973060B1 (ko) * 2017-10-20 2019-04-26 주식회사 녹십자 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물
CN109706164A (zh) * 2017-10-26 2019-05-03 深圳新诺微环生物科技有限公司 微环dna表达连接人和猴cd20与效应细胞抗原的桥接分子及其应用
CN109706163A (zh) * 2017-10-26 2019-05-03 深圳新诺微环生物科技有限公司 微环dna表达连接人与动物靶细胞与效应细胞的桥接分子及其应用
EP3705496A4 (en) 2017-11-01 2021-12-08 Chugai Seiyaku Kabushiki Kaisha ANTIBODY VARIANT AND ISOFORM WITH REDUCED BIOLOGICAL ACTIVITY
PT3749346T (pt) 2018-02-08 2024-09-05 Dragonfly Therapeutics Inc Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d
KR20200118824A (ko) 2018-02-08 2020-10-16 드래곤플라이 쎄라퓨틱스, 인크. 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법
CA3091424A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
WO2019166946A1 (en) 2018-02-28 2019-09-06 Pfizer Inc. Il-15 variants and uses thereof
EP3790585A4 (en) * 2018-05-07 2022-05-11 Dragonfly Therapeutics, Inc. PROTEIN-BINDING NKG2D, CD16 AND TUMOR-ASSOCIATED ANTIGEN
EP3797121B1 (en) 2018-05-23 2024-06-19 Pfizer Inc. Antibodies specific for cd3 and uses thereof
TWI803637B (zh) 2018-05-23 2023-06-01 美商輝瑞大藥廠 特異性針對gucy2c之抗體及其用途
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
SG11202101298XA (en) 2018-08-08 2021-03-30 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and a tumor-associated antigen
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
US12325757B2 (en) * 2018-12-21 2025-06-10 Zhejiang Shimai Pharmaceutical Co., Ltd. Protease cleavable bispecific antibodies and uses thereof
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
CN110357969B (zh) * 2019-05-27 2022-03-08 北京志道生物科技有限公司 一种GLP1-EGFa异源二聚体蛋白、功能及方法
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
CN110669137B (zh) * 2019-10-24 2021-07-16 高新 一种多特异性抗体及其制备方法和用途
KR20220114049A (ko) 2019-12-17 2022-08-17 화이자 인코포레이티드 Cd47, pd-l1에 특이적인 항체, 및 그의 용도
US20230043985A1 (en) 2019-12-18 2023-02-09 Pfizer Inc. Once daily cancer treatment regimen with a prmt5 inhibitor
EP4118105A2 (en) 2020-03-09 2023-01-18 Pfizer Inc. Cd80-fc fusion protein and uses thereof
CA3177024A1 (en) 2020-05-06 2021-11-11 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and clec12a
MX2022014180A (es) 2020-05-13 2022-12-02 Pfizer Metodos, terapias y usos para tratar cancer.
IL299939A (en) 2020-07-17 2023-03-01 Pfizer Therapeutic antibodies and their uses
MX2023003034A (es) 2020-09-14 2023-04-10 Pfizer Metodos, terapias y usos para tratar el cancer.
JP2024500093A (ja) * 2020-12-10 2024-01-04 ウーシー バイオロジクス アイルランド リミテッド P-カドヘリンに対する抗体及びその使用
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
CN114539420B (zh) * 2022-01-20 2024-05-17 荣昌生物制药(烟台)股份有限公司 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用
WO2023218320A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
WO2023242769A1 (en) 2022-06-17 2023-12-21 Pfizer Inc. Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof
WO2024003773A1 (en) 2022-07-01 2024-01-04 Pfizer Inc. 2,7-naphthyridine compounds as mastl inhibitors
AU2023302139A1 (en) 2022-07-05 2024-12-19 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024074977A1 (en) 2022-10-04 2024-04-11 Pfizer Inc. Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds
WO2024084364A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Compounds for the treatment of cancer
WO2024105563A1 (en) 2022-11-16 2024-05-23 Pfizer Inc. Substituted bicyclic pyridone derivatives
AU2024253142A1 (en) 2023-04-05 2025-10-16 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024213979A1 (en) 2023-04-10 2024-10-17 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024218686A1 (en) 2023-04-20 2024-10-24 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2025032521A1 (en) 2023-08-10 2025-02-13 Pfizer Inc. Methods, therapies and uses for treating cancer
WO2025094035A1 (en) 2023-11-01 2025-05-08 Pfizer Inc. Toll-like receptor agonists and conjugates thereof
WO2025109003A1 (en) 2023-11-21 2025-05-30 3B Pharmaceuticals Gmbh P-cadherin ligands

Family Cites Families (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0088994B1 (en) 1982-03-15 1991-06-19 Schering Corporation Hybrid dna, binding composition prepared thereby and processes therefor
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
WO1991001752A1 (en) 1989-07-27 1991-02-21 Fred Hutchinson Cancer Research Center Immunosuppressive monoclonal antibodies, hybridomas and methods of transplantation
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5811267A (en) 1990-10-29 1998-09-22 Chiron Corporation Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer antigens
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
DE69334287D1 (de) 1992-09-25 2009-07-09 Avipep Pty Ltd Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
SG55079A1 (en) 1992-12-11 1998-12-21 Dow Chemical Co Multivalent single chain antibodies
ES2199959T3 (es) 1993-02-04 2004-03-01 Borean Pharma A/S Procedimiento mejorado para el replegamiento de proteinas.
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
IT1271461B (it) 1993-12-01 1997-05-28 Menarini Ricerche Sud Spa Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0799244A1 (en) 1995-10-16 1997-10-08 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
ES2297861T3 (es) 1996-07-12 2008-05-01 Mcgill University Compuestos y metodos para modular la adhesion celular.
WO1998002462A1 (en) 1996-07-16 1998-01-22 Morphosys Gesellschaft Für Proteinoptimierung Mbh Immunoglobulin superfamily domains and fragments with increased solubility
WO1998041613A1 (en) 1997-03-14 1998-09-24 Otten Gillis R Targeted cytolysis of cancer cells
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6670453B2 (en) 1997-10-27 2003-12-30 Unilever Patent Holdings B.V. Multivalent antigen-binding proteins
US6485910B1 (en) 1998-02-09 2002-11-26 Incyte Genomics, Inc. Ras association domain containing protein
ID26964A (id) 1998-02-19 2001-02-22 Xcyte Therapies Inc Komposisi dan metode untuk pengaturan pengaktifan limfosit
CZ121599A3 (cs) 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
US6783961B1 (en) 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
EP1071752B1 (en) 1998-04-21 2003-07-09 Micromet AG CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
AU5728999A (en) 1998-07-28 2000-02-21 Micromet Ag Heterominibodies
WO2000023087A1 (en) 1998-10-21 2000-04-27 Sunol Molecular Corporation Polyspecific binding molecules and uses thereof
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
DE19905048A1 (de) 1999-02-08 2000-08-10 Gsf Forschungszentrum Umwelt Verwendung depletorisch oder mitogen wirkender Antikörper in der Immuntherapie
AU2001243142A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
US20020004587A1 (en) 2000-04-11 2002-01-10 Genentech, Inc. Multivalent antibodies and uses therefor
CA2405961A1 (en) 2000-04-26 2001-11-01 Elusys Therapeutics, Inc. Bispecific molecules and uses thereof
US20040047854A1 (en) 2001-07-27 2004-03-11 Black Roy A. Human disintegrin protein
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7319139B2 (en) 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
US20040053245A1 (en) 2001-02-05 2004-03-18 Tang Y. Tom Novel nucleic acids and polypeptides
AU2002240751A1 (en) 2001-03-09 2002-09-24 William Herman Targeted ligands
AU2002247826A1 (en) 2001-03-13 2002-09-24 University College London Specific binding members
US20030194406A1 (en) 2001-05-31 2003-10-16 Chiron Corporation P-cadherin as a target for anti-cancer therapy
US7189507B2 (en) 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
EP1399484B1 (en) 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
WO2003022987A2 (en) 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1293514B1 (en) 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
JP4386741B2 (ja) 2002-04-15 2009-12-16 中外製薬株式会社 scDbライブラリーの作成方法
EP1354600A1 (en) 2002-04-19 2003-10-22 Affimed Therapeutics AG Antibody combination useful for tumor therapy
US20040018493A1 (en) 2002-07-12 2004-01-29 Anastasio Alison E. Haplotypes of the CD3E gene
EP1541588A4 (en) 2002-07-18 2007-09-12 Cellfree Sciences Co Ltd SINGLE CHAIN ANTIBODIES AND USE THEREOF
KR20050048615A (ko) 2002-08-19 2005-05-24 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
EP1560597A4 (en) 2002-10-29 2007-06-27 Pharmacia Corp DIFFERENTIALLY EXPRESSED GENES INVOLVED IN CANCER, POLYPEPTIDES CODED THEREWITH, AND METHODS OF USING GENES
WO2004044000A2 (en) 2002-11-14 2004-05-27 Adherex Technologies, Inc. Compounds and methods for modulating functions of classical cadherins
EP2311870A1 (en) 2002-11-26 2011-04-20 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
MXPA05012080A (es) 2003-05-08 2006-02-22 Xcyte Therapies Inc Generacion y aislamiento de celulas t especificas al antigeno.
WO2004106381A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
AU2004242845B2 (en) 2003-05-31 2011-06-02 Amgen Research (Munich) Gmbh Human-anti-human CD3 binding molecules
JP2007537710A (ja) 2003-06-11 2007-12-27 ワイス 血小板糖タンパク質IBα改変体融合ポリペプチドおよびその使用法
US20050163782A1 (en) 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
DK1639011T3 (da) 2003-06-30 2009-02-16 Domantis Ltd Pegylerede enkelt-domæne antistoffer (dAb)
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US20070037204A1 (en) 2003-08-08 2007-02-15 Hiroyuki ABURANTAI Gene overexpressed in cancer
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2005028507A1 (en) 2003-09-24 2005-03-31 Monash University CRYSTAL STRUCTURE OF CD3ϵϜ/OKT3 COMPLEX
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
ATE435238T1 (de) 2004-05-05 2009-07-15 Micromet Ag Herstellung eines einkettigen fv antikörperfragments
SG155883A1 (en) 2004-06-03 2009-10-29 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
WO2006072620A1 (en) 2005-01-05 2006-07-13 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
EP2292796A1 (en) 2005-02-10 2011-03-09 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9889197B2 (en) 2005-04-15 2018-02-13 Macrogenics, Inc. Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin
JP5838021B2 (ja) * 2005-04-15 2015-12-24 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディとその使用
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
MX2007013304A (es) 2005-04-26 2007-12-13 Pfizer Anticuerpos de p-caderina.
CA2606227A1 (en) 2005-04-28 2006-11-02 Mcgill University Compounds and methods for modulating cadherin-mediated processes
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
US20100209437A1 (en) 2005-09-12 2010-08-19 Greg Elson Anti-CD3 Antibody Fromulations
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
PT1976880T (pt) 2005-12-21 2016-09-28 Amgen Res Munich Gmbh Composições farmacêuticas com resistência a cea solúvel
WO2007075672A2 (en) 2005-12-23 2007-07-05 Lankenau Institute For Medical Research Prognostic cancer markers
US20090169572A1 (en) 2006-02-28 2009-07-02 Oncotherapy Science, Inc, Methods for damaging cells using effector functions of anti-cdh3 antibodies
WO2007106507A2 (en) 2006-03-14 2007-09-20 Petrie Howard T Detection of gene expression in mixed sample or tissue
CN103073639A (zh) 2006-03-17 2013-05-01 比奥根艾迪克Ma公司 稳定的多肽组合物
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
US8535677B2 (en) 2006-06-06 2013-09-17 Oxford Biotherapeutics, Ltd. Antibody drug conjugate treatment of colorectal cancer
TWI615403B (zh) 2007-02-21 2018-02-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
EP4059964A1 (en) 2007-04-03 2022-09-21 Amgen Research (Munich) GmbH Cross-species-specific binding domain
EP2155783B2 (en) * 2007-04-03 2022-10-19 Amgen Research (Munich) GmbH Cross-species-specific cd3-epsilon binding domain
WO2008124858A2 (en) 2007-04-11 2008-10-23 F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. Targeted receptor
ES2456963T3 (es) 2007-06-04 2014-04-24 Rappaport Family Institute For Research In The Medical Sciences Agentes para el tratamiento de enfermedades inflamatorias y métodos para usar los mismos
EP2069401A4 (en) 2007-07-31 2011-02-23 Medimmune Llc MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
EP2178914A2 (en) 2007-08-15 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Monospecific and multispecific antibodies and method of use
UA100127C2 (ru) 2007-08-20 2012-11-26 Онкотерапи Саенс, Инк. Пептид cdh3 и лекарственное средство, содержащее его
EP2195341B1 (en) 2007-09-26 2017-03-22 UCB Biopharma SPRL Dual specificity antibody fusions
WO2009055937A1 (en) 2007-11-01 2009-05-07 The Royal Institution For The Advancement Of Learning/Mcgill University Altered n-cadherin processing in tumor cells by furln and proproteln convertase 5a (pc5a)
AR069495A1 (es) 2007-11-30 2010-01-27 Glaxo Group Ltd Construcciones de union de antigenos para el tratamiento de cancer o enfermedades inflamatorias (asma, artritis o artrosis)
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP5593560B2 (ja) * 2008-06-30 2014-09-24 オンコセラピー・サイエンス株式会社 放射性同位体標識で標識された抗cdh3抗体およびその使用
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
WO2010037835A2 (en) 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
US10981998B2 (en) 2008-10-01 2021-04-20 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
CA2738566C (en) 2008-10-01 2024-04-30 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
HUE030090T2 (en) 2008-10-01 2017-04-28 Amgen Res Munich Gmbh Cross-species-specific psmaxcd3 bispecific single chain antibody
WO2010040545A1 (en) 2008-10-06 2010-04-15 Novoplant Gmbh Proteolytically stable antibody formats
CA2740098A1 (en) 2008-10-10 2010-04-15 Valerie Odegard Tcr complex immunotherapeutics
US20110020221A1 (en) 2009-04-09 2011-01-27 The Johns Hopkins University Cancer stem cell expression patterns and compounds to target cancer stem cells
CA2760642A1 (en) 2009-05-01 2010-11-04 The University Of Tokyo Anti-cadherin antibody
WO2010136172A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
BR112012004710A2 (pt) 2009-09-01 2016-08-16 Abbott Lab imunoglobulinas de domínio variável duplo e uso das mesmas
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US20110064743A1 (en) 2009-09-09 2011-03-17 Hammond Philip W Human anti-cancer antibodies
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
CA2772945A1 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
CA2778334A1 (en) 2009-10-20 2011-04-28 Charlotte Mckee Anti-cd3 antibody dosing in autoimmune disease
US20120316071A1 (en) 2009-11-04 2012-12-13 Vaughn Smider Methods for affinity maturation-based antibody optimization
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
WO2011071541A2 (en) 2009-12-11 2011-06-16 The Scripps Research Institute Cadherin modulatory agents
JP2013514795A (ja) 2009-12-22 2013-05-02 ノバルティス アーゲー 治療における使用のための四価cd47抗体定常領域融合タンパク質
TW201125583A (en) 2009-12-23 2011-08-01 Bioalliance Cv Anti-EpCAM antibodies that induce apoptosis of cancer cells and methods using same
ES2701626T3 (es) 2009-12-28 2019-02-25 Oncotherapy Science Inc Anticuerpos anti-CDH3 y sus usos
CN102014475B (zh) 2010-01-08 2012-01-04 华为技术有限公司 资源映射、码分复用方法及装置
US20120294857A1 (en) 2010-01-11 2012-11-22 Trustees Of Dartmouth College Monomeric Bi-Specific Fusion Protein
EP2535358B1 (en) 2010-02-10 2017-12-20 Fujifilm RI Pharma Co., Ltd. Radioactive metal-labeled anti-cadherin antibody
PL2361936T3 (pl) 2010-02-25 2016-10-31 Cząsteczka wiążąca antygen i jej zastosowania
US8569450B2 (en) 2010-03-03 2013-10-29 Health Research Inc. CD3 epsilon immunogens and antibodies
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究(慕尼黑)有限責任公司 跨物種專一性之PSMAxCD3雙專一性單鏈抗體
RU2636461C2 (ru) 2010-05-03 2017-11-23 Дженентек, Инк. Композиции и способы для диагностики и лечения опухоли
WO2012021834A1 (en) 2010-08-13 2012-02-16 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
CA2808482C (en) 2010-08-16 2021-10-26 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
US8658774B2 (en) 2010-10-08 2014-02-25 City Of Hope Meditopes and related meditope-monoclonal antibody delivery systems, synthesis and therapeutic uses thereof
JP2014015396A (ja) 2010-10-29 2014-01-30 Perseus Proteomics Inc 高い親和性を有する抗cdh3抗体
PT2634194T (pt) 2010-10-29 2018-10-19 Perseus Proteomics Inc Anticorpos anti-cdh3 possuidores de elevada capacidade de internalização
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
EP2654792A4 (en) 2010-12-22 2016-05-11 Abbvie Inc HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF
UY33826A (es) 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión con dominios trivariables y sus usos
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
AR085633A1 (es) 2011-03-08 2013-10-16 Baylor Res Inst Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos
EP2683735A1 (en) 2011-03-10 2014-01-15 HCO Antibody, Inc. Bispecific three-chain antibody-like molecules
WO2012125850A1 (en) 2011-03-16 2012-09-20 Amgen Inc. Fc variants
CA2830349C (en) 2011-03-17 2019-07-16 The University Of Birmingham Re-directed immunotherapy
JP2014510084A (ja) 2011-03-17 2014-04-24 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド 二重特異性および単一特異性の非対称な抗体ならびにそれらの作製方法
WO2012129227A1 (en) 2011-03-22 2012-09-27 Baylor Research Institute Dendritic cells (dcs) targeting for tuberculosis (tb) vaccine
CA2831294A1 (en) 2011-03-25 2012-10-04 Baylor Research Institute Compositions and methods to immunize against hepatitis c virus
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
EP3536708A1 (en) 2011-04-19 2019-09-11 Pfizer Inc Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
JP2014518615A (ja) 2011-04-22 2014-08-07 エマージェント プロダクト デベロップメント シアトル, エルエルシー 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
US9376495B2 (en) 2011-05-21 2016-06-28 Macrogenics, Inc. Deimmunized serum-binding domains and their use in extending serum half-life
MX369220B (es) 2011-05-21 2019-10-31 Macrogenics Inc Moleculas que enlazan cd3 capaces de enlazar a cd3 humano y no humano.
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
WO2012162583A1 (en) 2011-05-26 2012-11-29 Ibc Pharmaceuticals, Inc. Design and construction of novel multivalent antibodies
CN112661848A (zh) 2011-05-27 2021-04-16 豪夫迈·罗氏有限公司 双靶向
MX2013014789A (es) 2011-06-16 2014-01-20 Novartis Ag Proteinas solubles para utilizarse como productos terapeuticos.
US9127061B2 (en) 2011-06-24 2015-09-08 Perseus Proteomics Inc. Anti-human P-cadherin (CDH3) recombinant antibody
WO2013012414A1 (en) 2011-07-18 2013-01-24 Medimmune, Llc Dosing regimens for treatment of cea-expressing cancers
CA2842649C (en) 2011-07-22 2020-01-21 Affimed Therapeutics Ag Multivalent antigen-binding fv molecule
RU2605390C2 (ru) 2011-08-23 2016-12-20 Рош Гликарт Аг Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
AR087608A1 (es) 2011-08-23 2014-04-03 Roche Glycart Ag Moleculas biespecificas de union a antigeno activadoras de celulas t
JP5925893B2 (ja) 2011-08-23 2016-05-25 ロシュ グリクアート アーゲー 二重特異性抗原結合分子
JP6060162B2 (ja) 2011-08-23 2017-01-11 ロシュ グリクアート アーゲー 2つのFabフラグメントを含むFc不含抗体および使用方法
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
WO2013041865A1 (en) 2011-09-22 2013-03-28 Immunocore Limited T cell receptors
EP2758438A1 (en) 2011-09-23 2014-07-30 Amgen Research (Munich) GmbH Bispecific binding molecules for 5t4 and cd3
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
DK2794658T3 (en) 2011-12-19 2017-06-19 Synimmune Gmbh BISPECIFIC ANTIBODY MOLECULE
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US20150037334A1 (en) 2012-03-01 2015-02-05 Amgen Research (Munich) Gmbh Long life polypeptide binding molecules
EP2848686B1 (en) 2012-04-04 2024-12-25 Perseus Proteomics Inc. Conjugate of anti-cdh3 (p-cadherin) antibody and drug
HK1208707A1 (en) 2012-04-20 2016-03-11 阿帕特夫研究和发展有限公司 Cd3 binding polypeptides
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US10647756B2 (en) * 2015-05-18 2020-05-12 Pfizer Inc. Humanized antibodies

Similar Documents

Publication Publication Date Title
JP2017520575A5 (enExample)
RU2016151645A (ru) Биспецифические гетеродимерные диантитела и их применение
JP2019524693A5 (enExample)
RU2018142544A (ru) Биспецифические связывающие белки и пути их применения
CN109071654B (zh) 靶向Fc受体样5的抗体及使用方法
US9815909B2 (en) Readily isolated bispecific antibodies with native immunoglobulin format
JP2017504578A5 (enExample)
JP2019520797A5 (enExample)
JP2018507188A5 (enExample)
JP2017527274A5 (enExample)
JP2020531438A5 (ja) Nkg2d、cd16、およびhla−eに結合するタンパク質
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
JP2020501531A5 (enExample)
JP2020525032A5 (enExample)
JP2018503380A5 (enExample)
JP2020517287A5 (enExample)
JP2017504577A5 (enExample)
JP2020508655A5 (enExample)
JP2019532619A5 (enExample)
JP2013545455A5 (enExample)
US20240209082A1 (en) Anti-cd96 antibodies and methods of use thereof
JP2012523848A5 (enExample)
CN105189557A (zh) 四价双特异性抗体
JP2012515556A5 (enExample)
RU2017108203A (ru) Слитые белки sirp-альфа с иммуноглобулином